Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $64.00

Mirum Pharmaceuticals (NASDAQ:MIRMFree Report) had its price target upped by Citigroup from $38.00 to $64.00 in a research note published on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

MIRM has been the topic of a number of other reports. Stifel Nicolaus reissued a buy rating and set a $48.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday. JMP Securities boosted their target price on shares of Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a market outperform rating in a research report on Tuesday. Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the stock an overweight rating in a research report on Tuesday. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $58.00 to $66.00 and gave the company a buy rating in a report on Monday. Finally, SVB Leerink cut their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating on the stock in a report on Monday, March 18th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of Buy and a consensus price target of $53.64.

Read Our Latest Report on MIRM

Mirum Pharmaceuticals Price Performance

MIRM opened at $31.14 on Tuesday. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $35.56. The company has a 50 day moving average of $25.49 and a two-hundred day moving average of $27.27. The company has a market cap of $1.47 billion, a P/E ratio of -8.39 and a beta of 1.10.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.14). Mirum Pharmaceuticals had a negative return on equity of 56.46% and a negative net margin of 69.67%. The firm had revenue of $69.22 million for the quarter, compared to analyst estimates of $69.71 million. On average, analysts expect that Mirum Pharmaceuticals will post -1.4 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Saira Ramasastry sold 5,000 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total value of $128,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Peter Radovich sold 4,303 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The disclosure for this sale can be found here. Insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. boosted its position in shares of Mirum Pharmaceuticals by 0.4% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 6,495,392 shares of the company’s stock valued at $191,744,000 after purchasing an additional 25,000 shares in the last quarter. Eventide Asset Management LLC boosted its position in shares of Mirum Pharmaceuticals by 14.4% during the 3rd quarter. Eventide Asset Management LLC now owns 3,958,579 shares of the company’s stock valued at $125,091,000 after purchasing an additional 499,378 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Mirum Pharmaceuticals by 34.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after purchasing an additional 704,659 shares in the last quarter. Cadian Capital Management LP boosted its position in shares of Mirum Pharmaceuticals by 34.8% during the 4th quarter. Cadian Capital Management LP now owns 1,934,922 shares of the company’s stock valued at $57,119,000 after purchasing an additional 500,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Mirum Pharmaceuticals by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,693,343 shares of the company’s stock valued at $53,510,000 after purchasing an additional 98,685 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Featured Articles

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.